US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by uniQure Inc.

< Previous 1 2 Next >
News headline image
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure to Announce Second Quarter 2026 Financial Results
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Pricing of Upsized $225 Million Public Offering
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces $150 Million Proposed Public Offering
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure to Announce First Quarter 2026 Financial Results
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces 2025 Financial Results and Provides Recent Company Updates
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure to Announce 2025 Financial Results
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Type A Meeting Scheduled with FDA
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure to Announce Third Quarter 2025 Financial Results
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Pricing of Upsized $300 Million Public Offering
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces $200 Million Proposed Public Offering
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
From uniQure Inc.
Via GlobeNewswire
Tickers HTGC QURE
News headline image
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure to Announce Second Quarter 2025 Financial Results
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
News headline image
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
From uniQure Inc.
Via GlobeNewswire
Tickers QURE
< Previous 1 2 Next >